Web Exclusives
These revenue cycle tips improve your financial performance and free up time to focus on what really matters — your oncology patients. Read More ›
On December 2, 2019, Merck announced that the FDA has granted priority review for its supplemental biologics license application for the anti–PD-1 agent pembrolizumab (Keytruda). If approved, the drug would be indicated as monotherapy to treat patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non–muscle-invasive bladder cancer who are ineligible for or have decided not to undergo cystectomy. Read More ›
Supporting patients with financial toxicity requires a human touch. Here are some ways
financial counselors help patients and improve revenue cycle in community oncology. Read More ›
Ovarian cancer not only exacts a high mortality rate, but also affects the physical, mental, and financial health of those diagnosed with the disease. Read More ›
Epidemiologic studies reveal population-based disparities in ovarian cancer morbidity and mortality rates. Read More ›
Genetic, menstrual, and other factors have been associated with increased risk of ovarian cancer. Read More ›
Current screening practices for ovarian cancer continue to result in late-stage diagnoses with consequent poor prognoses. Read More ›
- Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer
On November 15, 2019, the FDA approved crizanlizumab (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged ≥16 years with sickle-cell disease. Read More ›
3 ways to optimize financial counseling operations so you can reduce financial stress for your
patients and improve your oncology practice’s revenue cycle. Read More ›